Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 IMMvent Trial

被引：0
|
作者：
Reich, Kristian [1 ,2 ]
Gooderham, Melinda [3 ,4 ,5 ]
Thaci, Diamant
机构：
[1] SCIderm Res Inst, Hamburg, Germany
[2] Dermatologikum Berlin, Berlin, Germany
[3] Queens Univ, Sch Med, Kingston, ON, Canada
[4] SKIN Ctr Dermatol, Peterborough, ON, Canada
[5] Prob Med Res, Peterborough, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
10218
引用
收藏
页码：AB52 / AB52
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Kruger, J. G.
    Tsai, T.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H.
    Paul, C.
    [J]. EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
  • [2] Efficacy and safety of risankizumab (RZB) compared with adalimumab (ADA) in patients with moderate-to-severe plaque psoriasis: results from the phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Krueger, J. G.
    Tsai, T. -F.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H. Z.
    Paul, C.
    [J]. EXPERIMENTAL DERMATOLOGY, 2018, 27 : 9 - 10
  • [3] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, C.
    Crowley, J.
    Valdecantos, W.
    Wu, T.
    Reich, K.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 21
  • [4] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, Caitriona
    Crowley, Jeffrey
    Valdecantos, Wendell
    Wu, Tianshuang
    Reich, Kristian
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB55 - AB55
  • [5] Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
    Ohtsuki, Mamitaro
    Fujita, Hideki
    Watanabe, Mitsunori
    Suzaki, Keiko
    Flack, Mary
    Huang, Xin
    Kitamura, Susumu
    Valdes, Joaquin
    Igarashi, Atsuyuki
    [J]. JOURNAL OF DERMATOLOGY, 2019, 46 (08): : 686 - 694
  • [6] RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMHANCE
    Blauvelt, Andrew
    Papp, Kim A.
    Gooderham, Melinda
    Langley, Richard G.
    Leonardi, Craig
    Lacour, Jean-Philippe
    Philipp, Sandra
    Tyring, Stephen
    Bukhalo, Michael
    Wu, Jashin J.
    Bagel, Jerry
    Frankel, Ellen H.
    Pariser, David
    Flack, Mary
    Scherer, Joseph
    Geng, Ziqian
    Gu, Yihua
    Camez, Anne
    Thompson, Elizabeth H. Z.
    [J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 30 - 30
  • [7] Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
    Reich, Kristian
    Gooderham, Melinda
    Thaci, Diamant
    Crowley, Jeffrey J.
    Ryan, Caitriona
    Krueger, James G.
    Tsai, Tsen-Fang
    Flack, Mary
    Gu, Yihua
    Williams, David A.
    Thompson, Elizabeth H. Z.
    Paul, Carle
    [J]. LANCET, 2019, 394 (10198): : 576 - 586
  • [8] Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial
    Blauvelt, Andrew
    Leonardi, Craig L.
    Gooderham, Melinda
    Papp, Kim A.
    Philipp, Sandra
    Wu, Jashin J.
    Igarashi, Atsuyuki
    Flack, Mary
    Geng, Ziqian
    Wu, Tianshuang
    Camez, Anne
    Williams, David
    Langley, Richard G.
    [J]. JAMA DERMATOLOGY, 2020, 156 (06) : 649 - 658
  • [9] Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal
    Al-Janabi, A.
    Warren, R. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 220 - 221
  • [10] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Kim A. Papp
    Saskia de Vente
    Jiewei Zeng
    Mary Flack
    Byron Padilla
    Stephen K. Tyring
    [J]. Dermatology and Therapy, 2021, 11 : 487 - 497
12345